JAKARTA, IndonesiaDec. 10, 2015 /PRNewswire/ -- Local and multinational drug makers will continue to see strong revenue growth from the Asia Pacific markets. The key factors being the sustained expansion of private healthcare, improving healthcare access and the sale of higher value medicines. In addition, the APAC region remains highly vulnerable to disease outbreaks which will serve as a driver for pharmaceutical products such as vaccines and medical devices. Combined sales of prescription drugs and over-the-counter (OTC) medicines in APAC are expected to jump from USD285bn in 2014 to USD377bn by 2019.
Tailored to suit this fast growing industry, the 5th edition of CPhI South East Asia taking place during 6-8 April 2016 in Jakarta provides the must-attend platform where the regional pharma industry meets to leverage connections, knowledge and insight to spur business. Country Focus for 2016 is India, forecasted to be a top performing APAC country during 2014-2019 at 10.7% CAGR, and its relationship with Indonesia, expected to grow in the same timeframe by 8.3% CAGR. A preview of what will be debated in Jakarta and the immense potential of bilateral trade was given on December 1st in Mumbai by the Consulate General of Indonesia to India. Video at: https://youtu.be/wTv2DA2dzcg
The CPhI series of events drives growth and innovation in the global pharmaceutical industry, with leading exhibitions and online communities covering every step of the supply chain from drug discovery to finished dosage.
More than 100,000 visitors meet over 6,000 exhibitors at events in Europe, China, India, Japan, South East Asia, Russia, Brazil, Istanbul and Korea every year to exchange ideas, form alliances and conduct business on an international scale. CPhI also provides an online buyer & supplier directory at CPhI-Online.com.
Contact Person: Ivan Ferrari
Phone Number: +62-21-2930-5959 ext 138
SOURCE CPhI - UBM